PHASE 1 STUDY OF NAVITOCLAX (ABT-263) PLUS RITUXIMAB IN CD20-POSITIVE LYMPHOID MALIGNANCIES 15th Annual Meeting of the European-Hematology-Association Roberts, W., Advani, R., Kahl, B., Persky, D., Xiong, H., Cui, Y., Busman, T., Krivoshik, A., Enschede, S., Humerickhouse, R. FERRATA STORTI FOUNDATION. 2010: 371–371

View details for Web of Science ID 000279051301215